Gemtuzumab ozogamicin: time to resurrect?
作者信息
Ravandi Farhad, Estey Elihu H, Appelbaum Frederick R, Lo-Coco Francesco, Schiffer Charles A, Larson Richard A, Burnett Alan K, Kantarjian Hagop M
机构信息
Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA.
出版信息
J Clin Oncol. 2012 Nov 10;30(32):3921-3. doi: 10.1200/JCO.2012.43.0132. Epub 2012 Sep 17.
Abstract
摘要
相似文献
1
Gemtuzumab ozogamicin: time to resurrect?吉妥珠单抗奥唑米星：是时候重振雄风了？
J Clin Oncol. 2012 Nov 10;30(32):3921-3. doi: 10.1200/JCO.2012.43.0132. Epub 2012 Sep 17.
2
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.批准摘要：吉妥珠单抗奥唑米星用于复发急性髓系白血病
Clin Cancer Res. 2001 Jun;7(6):1490-6.
3
Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.低剂量吉妥珠单抗奥唑米星治疗老年复发性急性髓系白血病
Haematologica. 2003 Dec;88(12):ECR37.
4
Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.吉妥珠单抗奥唑米星：一种用于治疗急性髓系白血病的抗CD33免疫偶联物。
Expert Opin Biol Ther. 2008 Apr;8(4):527-40. doi: 10.1517/14712598.8.4.527.
5
Gemtuzumab ozogamicin: is there room for salvage?吉妥珠单抗奥唑米星：还有挽救的空间吗？
Blood. 2010 Oct 7;116(14):2618-9. doi: 10.1182/blood-2010-08-300871.
6
Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.吉妥珠单抗奥唑米星（麦罗塔）联合化疗方案治疗急性髓性白血病的试验。
Clin Lymphoma. 2002 Mar;2 Suppl 1:S24-8. doi: 10.3816/clm.2002.s.005.
7
Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions.缓解期后使用吉妥珠单抗奥唑米星治疗具有良好特征和合并症的老年急性髓性白血病患者。
Int J Hematol. 2010 Nov;92(4):673-4. doi: 10.1007/s12185-010-0711-9. Epub 2010 Oct 28.
8
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.在成年急性髓性白血病患者的诱导化疗中添加吉妥珠单抗奥唑米星：来自随机对照试验的个体患者数据的荟萃分析。
Lancet Oncol. 2014 Aug;15(9):986-96. doi: 10.1016/S1470-2045(14)70281-5. Epub 2014 Jul 6.
9
Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.吉妥珠单抗奥唑米星治疗伴有MLL/AF9的难治性急性髓系白血病达到完全分子缓解
Leuk Res. 2010 Jul;34(7):e152-3. doi: 10.1016/j.leukres.2009.12.006. Epub 2010 Jan 12.
10
[Gemtuzumab ozogamicin combined chemotherapy for elderly patients with acute myeloid leukemia].[吉妥珠单抗奥唑米星联合化疗用于老年急性髓系白血病患者]
Rinsho Ketsueki. 2014 May;55(5):508-17.
引用本文的文献
1
Current status and research directions in acute myeloid leukemia.急性髓细胞白血病的现状与研究方向。
Blood Cancer J. 2024 Sep 19;14(1):163. doi: 10.1038/s41408-024-01143-2.
2
DNA Damage Response Pharmacogenomic (DDR_PGx) Score Predicts Response to Chemotherapy Consisting of Gemtuzumab Ozogamicin in Pediatric AML: A Report from the Children's Oncology Group.DNA损伤反应药物基因组学（DDR_PGx）评分可预测儿童急性髓系白血病（AML）中由吉妥珠单抗奥唑米星组成的化疗方案的疗效：来自儿童肿瘤学组的报告。
Clin Cancer Res. 2025 Mar 3;31(5):890-898. doi: 10.1158/1078-0432.CCR-23-2073.
3
Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.抗体药物偶联物在癌症治疗中的应用：创新、挑战与未来方向。
Arch Pharm Res. 2024 Jan;47(1):40-65. doi: 10.1007/s12272-023-01479-6. Epub 2023 Dec 28.
4
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability.预测抗体药物偶联物的反应：聚焦于抗原的靶向性。
Oncologist. 2023 Nov 2;28(11):944-960. doi: 10.1093/oncolo/oyad246.
5
Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.连接子：抗体药物偶联物可控递送的保障
Pharmaceutics. 2022 Feb 11;14(2):396. doi: 10.3390/pharmaceutics14020396.
6
Blocking siglec-10 tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma.阻断唾液酸结合免疫球蛋白样凝集素10（Siglec-10）相关肿瘤巨噬细胞可改善抗肿瘤免疫并增强肝细胞癌的免疫治疗效果。
Exp Hematol Oncol. 2021 Jun 10;10(1):36. doi: 10.1186/s40164-021-00230-5.
7
The clinical development of antibody-drug conjugates - lessons from leukaemia.抗体药物偶联物的临床开发 - 白血病的经验教训。
Nat Rev Clin Oncol. 2021 Jul;18(7):418-433. doi: 10.1038/s41571-021-00484-2. Epub 2021 Mar 23.
8
Acute myeloid leukemia: current progress and future directions.急性髓系白血病：当前进展与未来方向。
Blood Cancer J. 2021 Feb 22;11(2):41. doi: 10.1038/s41408-021-00425-3.
9
Antibody-drug conjugates: smart weapons against cancer.抗体药物偶联物：对抗癌症的智能武器。
Arch Med Sci. 2019 Feb 18;16(5):1257-1262. doi: 10.5114/aoms.2019.83020. eCollection 2020.
10
Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse.急性早幼粒细胞白血病的蛋白质组学分析确定了与复发相关的两个蛋白质特征。
Proteomics Clin Appl. 2019 Jul;13(4):e1800133. doi: 10.1002/prca.201800133. Epub 2019 Feb 4.
本文引用的文献
1
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.在诱导化疗中添加吉妥珠单抗奥佐米星可改善老年急性髓细胞白血病患者的生存。
J Clin Oncol. 2012 Nov 10;30(32):3924-31. doi: 10.1200/JCO.2012.42.2964. Epub 2012 Jul 30.
2
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.吉妥珠单抗奥佐米星治疗初治成人急性髓系白血病的疗效（ALFA-0701）：一项随机、开放标签、3 期研究。
Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5.
3
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.鉴定能够从吉妥珠单抗奥佐米星治疗中获益的急性髓细胞性白血病患者：MRC AML15 试验的结果。
J Clin Oncol. 2011 Feb 1;29(4):369-77. doi: 10.1200/JCO.2010.31.4310. Epub 2010 Dec 20.
4
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.三种新型方案未能改善复发或难治性急性髓系白血病患者的结局：来自东部肿瘤协作组的报告。
Br J Haematol. 2010 Jan;148(2):217-25. doi: 10.1111/j.1365-2141.2009.07917.x. Epub 2009 Oct 5.
5
Anthracycline dose intensification in acute myeloid leukemia.急性髓系白血病中蒽环类药物剂量强化
N Engl J Med. 2009 Sep 24;361(13):1249-59. doi: 10.1056/NEJMoa0904544.
6
High-dose daunorubicin in older patients with acute myeloid leukemia.老年急性髓系白血病患者使用大剂量柔红霉素治疗
N Engl J Med. 2009 Sep 24;361(13):1235-48. doi: 10.1056/NEJMoa0901409.
7
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.全反式维甲酸、三氧化二砷和吉妥珠单抗奥唑米星对急性早幼粒细胞白血病的有效治疗。
J Clin Oncol. 2009 Feb 1;27(4):504-10. doi: 10.1200/JCO.2008.18.6130. Epub 2008 Dec 15.
8
Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia.老年晚期急性早幼粒细胞白血病患者接受低剂量吉妥珠单抗-奥佐米星治疗后获得持续分子缓解。
Haematologica. 2007 Sep;92(9):1273-4. doi: 10.3324/haematol.11329.
9
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.吉妥珠单抗奥唑米星（Mylotarg）用于首次复发的CD33阳性急性髓性白血病患者的疗效和安全性最终报告。
Cancer. 2005 Oct 1;104(7):1442-52. doi: 10.1002/cncr.21326.
10
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia.吉妥珠单抗奥唑米星（麦罗塔）作为分子复发急性早幼粒细胞白血病的单一治疗药物。
Blood. 2004 Oct 1;104(7):1995-9. doi: 10.1182/blood-2004-04-1550. Epub 2004 Jun 8.
Zotero 插件